Hv1 is a voltage-gated proton channel whose main function is to facilitate extrusion of protons from the cell. The development of effective channel blockers for Hv1 can lead to new therapeutics for the treatment of maladies related to Hv1 dysfunction. Although the mechanism of proton permeation in Hv1 remains to be elucidated, a series of small molecules have been discovered to inhibit Hv1. Here, we compute relative binding free energies of a prototypical Hv1 blocker on a model of human Hv1 in an open state. We use alchemical free energy perturbation techniques based on atomistic molecular dynamics simulations. The results support our proposed open state model, sheds light on the preferred tautomeric state of the blocker that binds Hv1, and lays the groundwork for future studies on adapting the blocker molecule for more effective channel blocking.
Introduction
The flux of ions across the cell membrane is regulated by a variety of ion channels. Hv1 is a voltage-dependent ion channel whose main function is to conduct protons through the cell membrane. Like voltage-dependent metal ion channels, the activation of Hv1 is regulated by voltage-sensing domains (VSDs), which are transmembrane modular units that detect changes in membrane potential. In contrast to voltage-dependent metal ion channels, Hv1 lacks a separate pore domain. The action of Hv1 contributes to physiological processes such as the production of reactive oxygen species, bioluminescence of dinoflagellates, and the maturation of human sperm. [1] [2] [3] Hyperactivity of Hv1 is related to various maladies such as allergic reactions, 4, 5 breast cancer metastasis, 6 and brain damage in ischemic stroke. 7 Hv1 inhibition was shown to reduce cancer metastasis and tumor. 8 More generally, the development of inhibitors to block the Hv1 channel may lead to therapeutic benefit for these Hv1-related diseases.
The structure of human Hv1 has not yet been experimentally determined. Human Hv1 is a homodimer, but each monomer has its own pore and can function independently. 9 We recently developed an atomistic model of the human Hv1 VSD open state using molecular dynamics (MD) simulations on the microsecond timescale in a hydrated lipid bilayer under an applied membrane potential. 10 Starting from the crystal structure of a chimeric construct based on mouse Hv1 in a putative closed state, 11 we generated closed and open state configurations exclusively of the applied membrane potential. The elicited conformational changes were consistent with the mechanism of activation proposed for metal ion channel VSDs. [12] [13] [14] The resulting structural models are supported by available experimental data. Further investigation of the open state model with respect to small molecule inhibitor binding would contribute to its validation and refinement and pave the way to designing more effective channel blockers.
Effective inhibition of Hv1 can be achieved by three types of molecules known to date: Zn 2+ , 15 peptide toxins such as Hanatoxin and C6, 16, 17 and guanidine derivatives. 18, 19 Both Zn 2+ and Hanatoxin would be poor therapeutic inhibitory agents for Hv1 due to their involvement in other cellular processes and ability to inhibit other voltage-gated ion channels. C6 is specific for Hv1 and has a lower dissociation constant than Zn 2+ and Hanatoxin, but its maximal inhibition is 50%. We focus on a representative guanidine derivative, 2-guanidinobenzimidazole (2GBI), to understand how it binds to Hv1. 2GBI and related compounds have the advantage that they can block both Hv1 at the plasma membrane and in intracellular compartments. The binding of 2GBI to Hv1 is described as a "foot in the door" mechanism of block, by which binding of the ligand prevents channel closure and slows down channel deactivation. 13 There is currently no known experimental structure of 2GBI in complex with Hv1, and the details of 2GBI binding are not completely known; however, mutagenesis experiments 18 suggest several key residues that play a role, including the selectivity filter D112 20 as well as F150 and R211 lining the central constriction region. 21 The structure of 2GBI (Figure 1 , top) was rationalized by the fact that Hv1 is inhibited by the guanidinium ion 9 which is structurally similar to the voltage-sensing arginine residues 22 in the S4 helix. 2GBI is a more effective inhibitor for Hv1 than guanidinium with the addition of its benzimidazole moiety. Despite that fact, replacement of one nitrogen atom on the five-membered ring by an oxygen atom resulted in less effective inhibition than even guanidinium. 13 Details of the binding site aside, this raises the question of the structure and charge distribution of 2GBI in relation to its tautomeric forms. 23 In this work, we study the binding of 2GBI to our open state human Hv1 model 10 using the alchemical free energy perturbation method with atomistic molecular dynamics simulations. We consider a series of six mutations previously shown to alter 2GBI apparent binding affinity, and compute relative binding free energies of these mutations compared to wild type Hv1 for two tautomeric forms of the inhibitor. This work reveals structural characteristics of 2GBI binding, emphasizes the prevalence of taut2 in binding Hv1, and may inform future efforts to optimize small molecule blockers of Hv1.
Methods

Ligand parameterization
Our study examines two tautomers of the positively charged 2GBI, depicted in Figure 1 . Both of these structures contain the guanidine/guanidinium-like moiety but have different centers of excess charge, located in either the guanidine region ("taut1") or in the central imidazole moiety ("taut2"). The force field for each tautomer was developed using the CHARMM General Force Field (CGenFF). 10, 24, 25 We generated reference structures from gas phase quantum mechanical (QM) geometry optimizations using the Psi4 software package. 26 We employed the MP2/6-31G* method [27] [28] [29] [30] [31] to stay consistent with CGenFF development. 25 The generated taut2 force field was modified to achieve better agreement regarding the geometry-optimized structures between the force field and QM calculations. The force field modification details and final parameters for both ligands can be found in the supplementary information (Figures S1-S3).
Docking calculations
Each tautomer of 2GBI was docked into Hv1 with AutoDock Vina version 1.1.2. 32 The membrane and all water molecules were removed during docking. The ligand dihedral angle, defined by the four atoms marked in Figure 1 (bottom), was held fixed in a planar conformation to prevent high-energy initial structures from strained non-planar conformations (see supplementary information). The resulting poses were filtered by a "reverse clustering" technique in which we clustered 33 in VMD 34 by root mean square deviation (RMSD) with a 3.0 Å cutoff and only retained poses distinct by more than this threshold. This process yielded a diverse set of starting poses ensuring good coverage of the multiple possible binding modes in the binding site, allowing minor differences between similar poses to be explored by our subsequent MD simulations. The resulting protein-ligand configurations were placed into a hydrated POPC lipid bilayer, and water molecules within 2 Å of the ligand were removed. Short (5 nanoseconds [ns]) MD simulations were run for the poses of each 2GBI tautomer using the NAMD software package, version 2.11. 35 Before running dynamics, 5000 minimization steps were performed using the conjugate gradient algorithm. Backbone alpha carbon atoms were fixed during minimization using harmonic position restraints with a force constant of 1 kcal/mol/Å 2 . The restraints were gradually turned off over 400 picoseconds (ps). Dynamics were then run with a 2 femtosecond (fs) time step in the isothermal-isobaric ensemble at a temperature of 300 K and a pressure of 1 bar. The Langevin thermostat was applied with a damping constant of 5 ps −1 , and the Langevin piston method was applied with an oscillation period of 200 fs and a damping time of 100 fs. Periodic boundary conditions were applied in all dimensions, with the z-axis normal to the membrane bilayer. The SHAKE algorithm was used to restrain all bonds to hydrogen atoms to their equilibrium values. Long-range electrostatic interactions were applied with the Particle Mesh Ewald (PME) algorithm; short-range Lennard-Jones and Coulombic interactions were calculated using a cutoff of 12 Å and a switching function applied beyond 10 Å. Bonded interactions and short-range forces were calculated every 2 fs, and long-range forces were calculated every 4 fs. An electric field was applied using a field vector of 0.14 kcal/(mol Å e) in the z direction, corresponding to a depolarizing membrane potential of +150 mV.
The final poses selected for free energy calculations were chosen based on the stability of the ligand in the binding position and evaluation of the hypothesized placement of 2GBI from experimental double-mutant cycle analyses. 18 Evaluation criteria and pose analysis are outlined in the supplementary information. The poses were equilibrated for at least 10 ns before free energy calculations.
Alchemical free energy calculations
Thermodynamic cycle used to compute relative binding free energies. The initial side chain from wild type Hv1 is shown in purple vdW spheres, and the final side chain after alchemical mutation of Hv1 is shown in green vdW spheres. The 2GBI ligand is drawn in yellow licorice. The membrane and water molecules are not shown for clarity. The relative binding free energy from experiment is calculated from ∆∆G = (∆G 2 − ∆G 1 ), which is thermodynamically equivalent to the alchemically computed relative binding free energy of ∆∆G = (∆G 4 − ∆G 3 ).
We apply the thermodynamic cycle approach as depicted in Figure 2 to calculate the change in the binding free energy of 2GBI from wild type Hv1 to the following protein mutations: D112E, V178A, S181A, V109A, R208K, and R211S. The first and last single letter codes denote the starting and final amino acids respectively. The relative binding free energy in this cycle is the difference in the free energies of mutation from the holo state to the apo state, i.e., ∆∆G = (∆G 4 − ∆G 3 ). The computed values were evaluated alongside relative binding energies from experimental mutagenesis studies 18 which correspond to processes ∆G 1 and ∆G 2 of the thermodynamic cycle; i.e., ∆∆G = (∆G 2 − ∆G 1 ).
Processes ∆G 3 and ∆G 4 of the thermodynamic cycle represent the alchemical transformations conducted computationally. The initial and final states for each of ∆G 3 and ∆G 4 are connected through a series of non-physical intermediate states ("λ windows") that comprise the alchemical transformation. This transformation is controlled by a parameter λ , starting from a value of zero at the initial state (i.e., wild-type protein residue) and reaching a value of one at the final state (i.e., mutant protein residue).
We compute the relative binding free energies using alchemical free energy perturbation with atomistic molecular dynamics simulations in NAMD. 35 Each alchemical transformation was conducted in both the forward and reverse directions (e.g., aspartate mutated to glutamate as well as glutamate mutated to aspartate) to facilitate convergence and sampling of overlapping phase space of the initial and final structures. The data from both directions were combined using the Bennett acceptance ratio (BAR) 36 to estimate the final free energies for each of ∆G 3 and ∆G 4 . The reported uncertainties of the relative binding free energies are the root sum square values of the ∆G 3 and ∆G 4 standard errors from BAR.
While the free energy difference between two states can be determined by the Zwanzig relationship, 37 this method is often slow to converge and results in poor phase space overlap. 38, 39 BAR minimizes the statistical variance between two ensembles with overlapping configurational space and thus yields the optimal averaging of the forward and reverse simulations.
The transformation of each forward or reverse direction was subdivided into 40 equivalently spaced λ windows, such that the first window ranges from λ = 0 to λ = 0.025 and the final window ranges from λ = 0.975 to λ = 1. With simple linear modification of interactions, "end point catastrophes" may result at λ → 0 or λ → 1, during which incoming atoms may appear where other particles already exist. 40 We avoid this by applying a soft-core potential on perturbed atoms to gradually scale their short-range nonbonded interactions with the rest of the system. 41 A dual-topology paradigm is applied throughout the alchemical transformation in which both the initial and final states are simultaneously present but non-interacting. Only nonbonded interactions for perturbed (incoming or outgoing) atoms contribute to the cumulative free energy. Van der Waals interactions were scaled as a function of λ across the full range from zero to one. Electrostatic interactions are introduced for the incoming atom(s) midway during the transformation (λ = 0.5), before which electrostatic interactions of the annihilating atoms are linearly decoupled.
Each window was started from the same initial hybrid structure and comprised 1000 minimization steps, 1 ns of equilibration, and 4 ns of production. The MD simulation settings were maintained as described earlier in this work. For each transformation, we simulate a total of 400 ns consisting of 5 ns for each of the 40 λ windows in the forward and reverse directions. The data from each λ window was subsampled to extract uncorrelated, effectively independent samples using the pyMBAR Python package. 42 The total simulation time over all tautomeric states and mutations represented in this study, including mutation S211R, as described in Results and Discussion, totals 5.6 microseconds.
We modified our standard setup for free energy calculations for mutations R208K and R211S. In these two cases, we additionally applied flat-bottom distance restraints to prevent hypermobility of the arginine and lysine residues. During normal MD simulations, these positively charged side chains are involved in salt bridge interactions with nearby acidic residues in which residue 208 is in proximity to D119, D123, and E192, and R211 is in proximity to D112, D185, and F150. However, these salt bridges are not maintained during the alchemical transformation with the dual-topology hybrid molecule because of the decoupled nonbonded interactions. In other words, considering the case of R208K, when arginine is mutated to lysine, arginine is fully interacting and present at the start, where λ = 0. In the final λ stage where λ = 1, arginine is now non-interacting and therefore does not form its usual contacts. These non-interacting, flexible side chains end up sampling an artificially broadened area of phase space, improperly reducing phase space overlap between the forward and reverse simulations and affecting the free energy estimate (see Results and Discussion). To avoid this and improve convergence of the calculations, we added additional distance restraints in these cases. The flat-bottom restraints were applied from the terminal nitrogen atom in arginine or the terminal carbon of lysine to surrounding protein residues not involved in the alchemical transformations. The reference distances were chosen to be large enough such that the restraint energies were zero when applied to the initial or final structure yet restrictive enough to prevent excessive side chain mobility during the free energy calculations (see supplementary information). The force constants on the restraint walls were set to 10 kcal/mol/Å.
Because some of our free energy calculations involved changes in formal charge, it was necessary to take particular care in these cases. Specifically, following the free energy simulations, we accounted for the energetic contribution arising from the change in net charge in the R211S mutation. To do so, we applied analytical corrections for the electrostatic finite-size effects as described by Rocklin et. al. 43 That being said, these corrections have almost no impact on the final relative binding free energies as we show in the Results and Discussion. 
Results and Discussion
We employed docking calculations, atomistic molecular dynamics simulations, and alchemical free energy calculations to examine the binding of 2GBI to human Hv1 (Figure 3 ). We computed relative binding free energies for a series of six protein mutations compared to wild type Hv1. Each set of binding free energy calculations was conducted for two tautomers of 2GBI, taut1 and taut2, which vary in their centers of excess charge (Figure 1 ). Our results show general qualitative agreement with experimental mutagenesis data and suggests that one tautomer may be more relevant than the other in the bound configuration. We also discuss some limitations when carrying out alchemical transformations of flexible protein side chains.
Positioning of 2GBI tautomers within the Hv1 open state
From the docking calculations, we employed a "reverse clustering" approach to identify 2GBI binding poses (see Methods). That is to say, because the binding mode is unknown and given that docking does not predict definitive binding modes, we aimed to sample a variety of potential poses of 2GBI within the expected binding region in order to find the most reasonable binding mode. The resulting poses from docking calculations were assessed using the predicted interactions between 2GBI and Hv1 from experimental mutagenesis data. 18 Hong et al. proposed a model of binding involving residues D112, F150, S181, and R211. We selected binding poses where 2GBI was in close proximity and interacted with these residues. Based on these poses, we note likely contacts with two additional residues, D185 and F182. Our binding pose contains the following features ( Figure  4) : stabilization of the benzimidazole ring by hydrophobic residues F150, I154, and F182; hydrogen bond donation from one of the imidazole NH groups to acidic residue D185; and interactions of the guanidine region with the charged residues D112 and R211. We chose the same binding pose for taut1 and taut2.
Our pose is distinct from that proposed in recent work by Gianti et al. 44 who performed induced fit docking of 2GBI (our taut1 structure). They obtained a binding pose in which 2GBI is roughly in the same region of Hv1 but angled differently such that the benzo moiety of 2GBI is closer to S1 than to S3 as in our pose. The location of the guanidine group in our pose pointing to R211 is more consistent with experimental work. 18 Differences in binding configuration may be in part due to differences in our open state models. 10 Gianti's study did not consider alternate tautomers nor involved free energy calculations.
Calculation of relative binding free energies
We calculated the relative binding free energies for two tautomers of 2GBI binding to wild type and mutant Hv1 using our open state model. The relative binding free energies were computed using molecular dynamics simulations with alchemical free energy perturbation. We consider six Hv1 mutations, previously reported by Hong et al. using electrophysiological and site-directed mutagenesis experiments. 18 Compared to 2GBI binding to wild type Hv1, these mutations comprise the effects of unfavorable binding (D112E, S181A), favorable binding (V178A, V109A), and relatively no change in the binding free energy (within~0.1 kcal/mol: R208K, R211S). These values are plotted in Figure 5 and listed in Table 1 . Binding free energies of 2GBI (taut1 and taut2) to Hv1, for mutant Hv1 compared to wild type Hv1. The data presented here is plotted in Figure 5 .
Protein mutations which involve charged side chains (D112E, R208K, and R211S) are more challenging cases for which to compute binding free energies compared to mutations having neutral residue end states. The case for D112E involves charge movement by the addition of a methylene group, the R208K mutation changes the charge density of the cationic region, and the R211S transformation changes the charge of the system from neutral to -1 e. There are greater disparities in the relative binding free energies of taut1 and taut2 for these three mutations, with taut2 values closer to experiment. Notably, in the case of D112E, the mutation induces a shift in the taut1 ligand orientation as 2GBI rotates to prevent crowding of the glutamate residue and to maximize interactions of its guanidine moiety ( Figure 6 ). It appears that the charge distribution of taut2 is better able to facilitate stabilizing hydrogen bonding interactions of the 2GBI imidazole moiety with residue D185. That being said, the mutation from aspartate to glutamate to yield a longer side chain at position 112 seems to also result in less effective protein-ligand interactions with taut2, though not to the same extent as taut1. This crowding may explain the unfavorable binding represented by the positive relative binding free energy.
Of the mutations considered here, the V178A mutation is most favorable for binding 2GBI, with an experimental relative binding free energy of -0.56 ± 0.05 kcal/mol compared to wild type. In contrast, our predicted value was between 0.7 and 0.8 kcal/mol for both tautomers, indicating binding becomes less favorable. We wondered if the experimental value reflected additional protein rearrangements not captured in the timescale of our MD simulations. To explore this further, we focused on a nearby aromatic residue, F182, in proximity to both V178 and the benzo moiety of 2GBI. This residue has been found to play a role in 2GBI binding via π-stacking interactions. 45 We hypothesized that F182 may reorient itself, occupying some of the space from the mutation of valine to alanine, to better interact with the bound ligand. We evaluated the energetic contribution of this putative conformational change by computing the potential of mean force for rotating the F182 χ 1 dihedral angle. Our results (see supplementary information) did not support this theory but rather suggested an energetic cost of around 8 kcal/mol for the F182 aromatic ring being in an off-centered parallel configuration with the 2GBI aromatic moiety.
Hysteresis in free energy calculations involving "floppy" residues
One way we can evaluate convergence in our free energy calculations is by analyzing the histogram overlap of work values from the forward and reverse processes. 46 We observe that mutations involving flexible and charged side chains, such as arginine and lysine, are more prone to have poor overlap, signifying inadequate sampling of overlapping regions of phase space during the alchemical transformations. This presumably arises from the scaling of nonbonded interactions. Towards the start of the transformation (λ close to 0), the incoming atoms are mostly decoupled from, or not interacting with, the rest of the system. Similarly, at states where λ is close to 1 near the end of the alchemical transformation, the outgoing atoms are decoupled with the rest of the system. The decoupled nonbonded interactions may "free" the flexible, charged side chains to adopt various nonphysical conformations.
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A B E112 E112 D185 D185 Figure 6 . 2GBI bound to the human Hv1 D112E mutant in the (A) taut2 and (B) taut1 systems. The ligand and surrounding residues are displayed in licorice representation, and the oxygen atoms of waters within 3 Å of the ligand are shown as light blue spheres. The charge distribution of 2GBI taut2 (see Figure 1 ) allows for improved protein-ligand interactions in the D112E structure due to its more positively charged imidazole region. On the other hand, taut1 reorients to maximize the interactions of its more positively charged guanidine moiety with both E112 and D185.
We illustrate this hysteresis in context of the R208K Hv1 mutation, focusing on the arginine residue. In wild type Hv1, the measure of the R208 χ 1 dihedral angle ( Figure 7A ) averages around 154 • in equilibrium simulations (histogrammed in Figure  7B ), and R208 is in close proximity to the acidic side chains E119 and E192. However, during free energy calculations with the scaled nonbonded interactions, the side chain pivots around such that R208 is artifactually outside the channel ( Figure 7C ), and the χ 1 dihedral angle values are inconsistent with the range expected from wild type Hv1 simulations ( Figure 7D ). The lack of fully coupled van der Waals and electrostatic interactions of the floppy, charged residue with the rest of the system interrupts native ionic interactions and leads to unnatural wandering of the side chain in simulations of these artificial intermediate states. The sampled unphysical configurations were directly correlated with poor overlap between the forward and reverse transformations, evidenced here by bimodal histograms of the work values from the forward and reverse transformations ( Figure 7E ). Similar observations were made for the lysine χ 1 dihedral angle.
We reduced this hysteresis by imposing a series of flat-bottom distance restraints with nearby interacting acidic residues (see Methods; details in supplementary information). This yielded fewer abnormal side chain configurations (Figure 7F -G) and better overlap of the forward and reverse work ( Figure 7H ).
Further exploration on R211S
The mutation whose relative binding free energy is least consistent with experimental results is R211S, predicted to be overly favorable by -6.3 kcal/mol for taut1 and -7.1 kcal/mol for taut2 (experimental reference value is 0.1 kcal/mol). We considered whether a potential contribution may have been the change in total charge of the system. The mutation from positively charged arginine to neutral serine changes the system's net charge from neutral to -1 e. Our simulations employ the particle-mesh Ewald (PME) method for treatment of long-range electrostatics in the periodic system. However, PME enforces neutrality by introducing a uniform neutralizing background charge. Therefore, with the non-neutral end state, the calculated free energy not only has the expected contribution of turning off the arginine charge but also undesired contribution for turning on the neutralizing background charge. We corrected for the electrostatic finite-size effects by applying an analytical correction based on the Poisson-Boltzmann continuum electrostatics model in CHARMM (version c40b1). 43, 47 The corrections to the binding free energy were not trivial when considered individually (apo = -3.1042 kcal/mol, taut1 = -3.1030 kcal/mol, taut2 = -3.1019 kcal/mol). However, they become negligible when considering relative binding free energies. Thus, both uncorrected and corrected free energies agree well as to the relative binding free energy. As a result, we believe that the change in net charge is not the primary reason for poor agreement of the experimental and computed R211S relative binding free energies.
We investigated the possibility of unconverged conformational sampling as a cause for the R211S outlying behavior. We performed the same transformation in the opposite direction, i.e., preparing the system with S211 and perturbing to R211. The S211 structures for the apo, taut1-bound, and taut2-bound states came from the end of the respective R211S transformations. Each configuration was equilibrated for 5 ns before the S211R free energy calculations. We maintained the same λ schedule and simulation parameters as described earlier. In some cases, we saw that the binding free energy for Arg → Ser (R211S) is not the same as the negative of Ser → Arg (S211R), where we take the negative value in order to adequately compare the free energy change in the same direction. We subsequently refer to this mutation as −1 × S211R. The free energies for R211S and −1 × S211R should be the same ideally, as free energy is a state function which is independent of the path or direction taken between two states. This discrepancy was observed for the apo protein and the taut1-bound protein such that with S211R, the disagreement with experiment decreased for both taut1 and taut2 with computed relative binding free energies of -5.9 kcal/mol and -1.3 kcal/mol respectively ( Figure 8A , brown vs. pink). In this plot, taut1 seems to be more consistent between R211S and −1 × S211R. However, the plotted values are relative binding free energies where the apo value is subtracted from each of the taut1 and taut2 values. From the thermodynamic cycle shown in Figure 2 , the ∆G 3 of apo and ∆G 4 of taut1 change by about 4 kcal/mol between R211S and −1 × S211R, but taut2 is relatively more consistent since its ∆G 4 value only changes by about 1 kcal/mol between R211S and −1 × S211R ( Figure 8B ). We posit that this discrepancy may arise from differences in R211 interactions with other protein residues as well as differences in hydration patterns in the local region. In simulations of wild type Hv1, R211 is a hydrogen bond donor to two aspartate residues, D112 and D185 ( Figure 9A ). These interactions are disrupted when the arginine is mutated to serine, and there is a slight influx of waters to the mutation site to stabilize D185. The S211R mutation reintroduces arginine, but R211 does not reform native contacts with D185, now surrounded by the water molecules ( Figure 9B ). This may occur if the system is slower to dispel waters from the pore than it is to allow waters inside, especially near the buried region of the mutated residue ( Figure 10 ). Hence the underlying end states of R211 are not the same in the R211S and S211R mutations, potentially due to insufficient rearrangement of the surrounding solvent network. In other words, non-overlapping ensembles are being sampled in the R211S and S211R transformations, precluding reasonable comparison of these calculations with experimental mutagenesis results. Thus, our results for this transformation are reported here, but the apparent agreement between ∆∆G FEP and ∆∆G expt for taut2 and the −1 × S211R mutation ( Figure 8A ) cannot be used meaningfully to assess the validity of our structural model due to the difficulties with this particular calculation. Figure 2 ). For example, the apo protein value represents ∆G 3, R211S − (−1 × ∆G 3, S211R ). This value should be zero since free energy is a state function which is independent of the path taken.
Conclusions
In this study, we employed free energy calculations with atomistic molecular dynamics simulations to characterize the binding of 2GBI to Hv1 as a foundational step to optimize small molecule blockers of Hv1. Our molecular insights of the binding mechanism of 2GBI to Hv1 agree with double-mutant cycle experiments, helping to validate our structural model for the channel and the bound state.
The mutations that were most computationally challenging were those involving charged side chains: D112E, R208K, and R211S. The R211S calculation might be further examined using enhanced sampling methods such as REST2, with the inclusion of protein side chains and water molecules in the vicinity of R211.
Results from alchemical free energy calculations show that both taut1 and taut2 tautomers are comparable in most relative binding free energies calculated. The taut1 structure is limited in its extent of forming protein-ligand contacts without the protonated imidazole region. We reason that taut2, the tautomer with excess charge in the imidazole region, is likely the primary state to bind Hv1. We hope to investigate the extent to which free energy calculations may be used to design new compounds based on the 2GBI scaffold, particularly with an imidazole-based pharmacophore with substitutions at the 2-position that stabilize ring protonation, for more effective binding to Hv1 for potential therapeutic benefit. . When mutating the system with S211 back to R211, the number of water molecules decrease near D112 instead of near D185 (left subplot, middle group, orange → green bars). It might be expected that the blue bars (wild type protein with R211) and the green bars (twice mutated protein also with R211) should be the same in all three systems. Both the apo and taut1 systems show marked differences between the two R211 states, whereas taut2 is more consistent in hydration around the mutated and acidic residues with R211.
